Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2011

Open Access 01-12-2011 | Research

Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer

Authors: Qingsong Yin, Xianfeng Zha, Lijian Yang, Shaohua Chen, Yubing Zhou, Xiuli Wu, Yangqiu Li

Published in: Journal of Hematology & Oncology | Issue 1/2011

Login to get access

Abstract

Background

Our previous study had amplified antigen-specific full-length TCR α and β genes of clonally expanded T cells in the peripheral blood (PB) of patients with diffuse large B-cell lymphoma (DLBCL). The transfer of T cell receptor (TCR) genes endows T cells with new antigen specificity. Therefore, the aim of this study is to generate diffuse large B cell lymphoma (DLBCL)-specific T cells by T cell receptor (TCR) gene transfer.

Materials and methods

Two different eukaryotic expression plasmids harboring TCR Vα6 and TCR Vβ13 genes specific for DLBCL-associated antigens were constructed and subsequently transferred into human T cells using Nucleofector™ technique. The expression of targeted genes in TCR gene-modified cells was detected by real-time PCR, and western blot using TCR Vβ antibody. The specific cytotoxicity of TCR gene-transferred T cells in vitro was estimated using a lactate dehydrogenase (LDH) release assay.

Results

Two different eukaryotic expression plasmids harboring TCR Vα6 and TCR Vβ13 genes specific for DLBCL-associated antigens were constructed and subsequently transferred into T cells from healthy donors. Specific anti-DLBCL cytotoxic T lymphocytes (CTL) could be induced by transduction of specific TCR gene to modify healthy T cells. The transgene cassette of TCR Vβ13-IRES-TCR Vα6 was superior to the other in the function of TCR-redirected T cells.

Conclusions

Specific anti-DLBCL cytotoxic T lymphocyte (CTL) could be inducted by transduction of specific TCR gene to modify healthy T cells.
Appendix
Available only for authorised users
Literature
1.
Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity. 1999, 10: 281-287. 10.1016/S1074-7613(00)80028-X.CrossRefPubMed
2.
Blattman JN, Greenberg PD: Cancer immunotherapy: A treatment for the masses. Science. 2004, 305: 200-205. 10.1126/science.1100369.CrossRefPubMed
3.
Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins RJ: Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 2008, 42: 201-205. 10.1038/bmt.2008.135.CrossRefPubMed
4.
Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007, 25: 4938-4945. 10.1200/JCO.2007.11.6053.CrossRefPubMed
5.
Porter DL, Collins RH, Hardy C, Kernan NA, Drobyski WR, Giralt S, Flowers ME, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R, Antin JH: Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000, 95: 1214-1221.PubMed
6.
Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986, 233: 1318-1321. 10.1126/science.3489291.CrossRefPubMed
7.
Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005, 23: 2346-2357. 10.1200/JCO.2005.00.240.PubMedCentralCrossRefPubMed
8.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002, 298: 850-854. 10.1126/science.1076514.PubMedCentralCrossRefPubMed
9.
Popescu MC, Robb RJ, Batenjany MM, Boni LT, Neville ME, Pennington RW, Neelapu SS, Kwak LW: A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood. 2007, 109: 5407-5410. 10.1182/blood-2006-08-039446.PubMedCentralCrossRefPubMed
10.
Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R: Phase I study of adoptive T-cell therapy using antigen-specific CD8+T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006, 24: 5060-5069. 10.1200/JCO.2006.07.1100.CrossRefPubMed
11.
Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN: Immunotherapy through TCR gene transfer. Nat Immunol. 2001, 2: 957-61. 10.1038/ni1001-957.CrossRefPubMed
12.
Heemskerk MHM: T-cell receptor gene transfer for the treatment of leukemia and other tumors. Haematologica. 2010, 95: 15-19. 10.3324/haematol.2009.016022.PubMedCentralCrossRefPubMed
13.
Griffioen M, van Egmond HM, Barnby-Porritt H, van der Hoorn MA, Hagedoorn RS, Kester MG, Schwabe N, Willemze R, Falkenburg JH, Heemskerk MH: Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 2008, 93: 1535-1543. 10.3324/haematol.13067.CrossRefPubMed
14.
Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI: Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999, 163: 507-513.PubMed
15.
Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H: Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood. 2005, 106: 3062-3067. 10.1182/blood-2005-01-0146.CrossRefPubMed
16.
Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, Strand S, Romero P, Huber C, Sherman LA, Theobald M: Cooperation of human tumor-reactive CD4+ and CD8+T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 2005, 22: 117-129. 10.1016/j.immuni.2004.12.005.CrossRefPubMed
17.
Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD: Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000, 74: 8207-8212. 10.1128/JVI.74.17.8207-8212.2000.PubMedCentralCrossRefPubMed
18.
Orentas RJ, Bircher LA, Roskopf S: Retroviral transfer of T-cell receptor genes produces cells with a broad range of lytic activity. Scand J Immunol. 2003, 58: 33-42. 10.1046/j.1365-3083.2003.01277.x.PubMedCentralCrossRefPubMed
19.
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006, 314: 126-129. 10.1126/science.1129003.PubMedCentralCrossRefPubMed
20.
Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006, 24: 3121-3127. 10.1200/JCO.2005.05.1003.CrossRefPubMed
21.
Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ: Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: Engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica. 2010, 95: 126-134. 10.3324/haematol.2009.006486.PubMedCentralCrossRefPubMed
22.
Yin Q, Tan H, Chen S, Yang L, Ye J, Li Y: Characterization of conserved CDR3 sequence of TCR α- and β-chain genes in peripheral blood T cells from patients with diffuse large B-cell lymphoma. Hematology. 2010, 15: 48-57. 10.1179/102453310X12583347009694.CrossRefPubMed
23.
Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T: IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther. 2000, 1: 376-382. 10.1006/mthe.2000.0050.CrossRefPubMed
24.
Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ: Exploiting T cell receptor genes for cancer immunotherapy. Clin Exp Immunol. 2005, 139: 167-172. 10.1111/j.1365-2249.2005.02715.x.PubMedCentralCrossRefPubMed
25.
Engels B, Uckert W: Redirecting T lymphocyte specificity by T cell receptor gene transfer - a new era for immunotherapy. Mol Aspects Med. 2007, 28: 115-142. 10.1016/j.mam.2006.12.006.CrossRefPubMed
26.
Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA: Enhanced anti-tumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006, 66: 8878-886. 10.1158/0008-5472.CAN-06-1450.PubMedCentralCrossRefPubMed
27.
Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA: Enhanced antitumor activity of T cells engineered to express T cell receptors with a second disulfide bond. Cancer Res. 2007, 67: 3898-3903. 10.1158/0008-5472.CAN-06-3986.PubMedCentralCrossRefPubMed
28.
Heitzer M, Eckert A, Fuhrmann M, Griesbeck C: Influence of codon bias on the expression of foreign genes in microalgae. Adv Exp Med Biol. 2007, 616: 46-53. full_text.CrossRefPubMed
29.
Scholten KB, Kramer D, Kueter EW, Graf M, Schoedl T, Meijer CJ, Schreurs MW, Hooijberg E: Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol. 2006, 119: 135-145. 10.1016/j.clim.2005.12.009.CrossRefPubMed
30.
Holst J, Vignali KM, Burton AR, Vignali DA: Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods. 2006, 3: 191-197. 10.1038/nmeth858.CrossRefPubMed
31.
Leisegang M, Engels B, Meyerhuber P, Kieback E, Sommermeyer D, Xue SA, Reuss S, Stauss H, Uckert W: Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med. 2008, 86: 573-583. 10.1007/s00109-008-0317-3.CrossRefPubMed
32.
Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, Strand S, Romero P, Huber C, Sherman LA, Theobald M: Cooperation of human tumor-reactive CD4+ and CD8+T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 2005, 22: 117-129. 10.1016/j.immuni.2004.12.005.CrossRefPubMed
33.
Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T: Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood. 2005, 106: 470-476. 10.1182/blood-2004-09-3663.CrossRefPubMed
34.
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, Shirakata T, Nishida S, Taniguchi Y, Kawase I, Oji Y, Sugiyama HA: WT1 protein-derived, naturally processed 16-mer peptide, WT1 (332), is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4 (+) T cells. Microbiol Immunol. 2008, 52: 591-600. 10.1111/j.1348-0421.2008.00080.x.CrossRefPubMed
Metadata
Title
Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer
Authors
Qingsong Yin
Xianfeng Zha
Lijian Yang
Shaohua Chen
Yubing Zhou
Xiuli Wu
Yangqiu Li
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2011
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-4-2

Other articles of this Issue 1/2011

Journal of Hematology & Oncology 1/2011 Go to the issue

Research

T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3

Review

Targeting insulin-like growth factor axis in hepatocellular carcinoma

Short report

Gene expression profiles in BCL11B-siRNA treated malignant T cells

Review

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

Review

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors

Research

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits